Skip to main content
. 2017 Sep 12;69(10):1937–1948. doi: 10.1002/art.40196

Figure 2.

Figure 2

Clinical response in period 2 of the C‐EARLY study, showing the full analysis set. A, Proportion of patients in whom low disease activity (LDA) was maintained, and proportion in whom remission (REM) was maintained, at week 104. Odds ratios (ORs) with 95% confidence intervals (95% CIs) and corresponding P values are from a logistic regression model with factors for treatment, region, time since rheumatoid arthritis (RA) diagnosis, and sustained remission status at week 52. Only patients with disease in sustained remission at week 52 were included in the analysis for maintained remission at week 104. Nonresponder imputation was used for missing data. B, Proportion of patients with low disease activity, defined as a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate (DAS28‐ESR) of ≤3.2. C, Proportion of patients with disease in remission, defined as a DAS28‐ESR of <2.6. D, Proportion of patients with normative physical function, defined as a Health Assessment Questionnaire disability index score of ≤0.5. B–D show results of post hoc analyses. The last observation carried forward approach was used to impute missing data. CZP = certolizumab pegol. See Patients and Methods for descriptions of groups.